JAAD case reports, 2(2), 150152
In one single-center trial of 72 subjects using a controlled-adverse-environment model, the T4 eye drop did not meet its co-primary endpoints (ocular discomfort and inferior corneal staining) at the primary time point, but it did produce statistically significant improvements on several secondary endpoints, including central and superior corneal staining, with no adverse events reported
Your personal schedule will depend on the peptides used, your health history, lab results when needed, and how your body responds during your treatment cycle
Chronic low-grade inflammation, often called "inflammaging," is now recognized as a central driver of biological aging, contributing to cardiovascular disease, neurodegeneration, insulin resistance, and loss of muscle mass
We also acknowledge the facility supports by Medical Research Center at the Eighth Affiliated Hospital, Sun Yat-sen University
Brain Res 397: 137144